JARDIANCE: Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE,
reactions such as angioedema have occurred; patients on dialysis.
TRADJENTA: Hypersensitivity to linagliptin, or any of the excipients in TRADJENTA,
reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.
TRIJARDY XR: Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease,
or dialysis; acute or chronic metabolic acidosis, including diabetic ketoacidosis; hypersensitivity to empagliflozin,
linagliptin, metformin, or any of the excipients in TRIJARDY XR, reactions such as anaphylaxis,
angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.
WARNINGS AND PRECAUTIONS
Lactic Acidosis: TRIJARDY XR
There have been cases of metformin-associated lactic acidosis, including fatal cases. These cases had a
subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain,
respiratory distress, or increased somnolence; however, hypothermia, hypotension, and resistant
bradyarrhythmias have occurred with severe acidosis. Additional findings included elevated blood lactate
concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an
increased lactate: pyruvate ratio, metformin plasma levels generally >5 mcg/mL.
If lactic acidosis is suspected, immediately discontinue TRIJARDY XR and institute
general supportive measures promptly in a hospital setting. Prompt hemodialysis is recommended to
correct the acidosis.
Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur,
instruct them to discontinue TRIJARDY XR and promptly notify their healthcare provider.
Recommendations to reduce the risk include:
- Renal Impairment: Obtain eGFR prior to initiating and annually or more frequently in patients at increased risk of developing renal impairment.
- Drug Interactions: More frequent monitoring is recommended when administered with drugs that impair
renal function, result in hemodynamic change, interfere with acid-base balance, or increase
- Age 65 or Greater: Assess renal function more frequently.
- Radiological Studies with Contrast: Stop TRIJARDY XR at the time of, or prior to,
an iodinated contrast imaging procedure in patients with an eGFR of <60 mL/min/1.73m2; patients
with a history of hepatic impairment, alcoholism or heart failure; or patients who will be administered
intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the procedure and restart
TRIJARDY XR if renal function is stable.
- Surgery and Other Procedures: Discontinue while patients have restricted food and fluid intake.
- Hypoxic States: Discontinue in conditions associated with hypoxemia.
- Excessive Alcohol Intake: Warn patients against excessive alcohol intake.
- Hepatic Impairment: Avoid use in patients with hepatic disease.
Pancreatitis: TRADJENTA, TRIJARDY XR
Acute pancreatitis, including fatal pancreatitis, has been reported in patients taking linagliptin, a
component of TRADJENTA or TRIJARDY XR. Take careful notice of potential signs and symptoms
of pancreatitis and, if suspected, promptly discontinue and initiate appropriate management. It is unknown
whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis
while using TRADJENTA or TRIJARDY XR.
Heart Failure: TRADJENTA, TRIJARDY XR
Heart failure has been observed with two other members of the dipeptidyl peptidase-4 (DPP-4) inhibitor
class. Consider risks and benefits of TRADJENTA or TRIJARDY XR in patients at risk for
heart failure, such as those with a prior history of heart failure and a history of renal impairment.
Monitor patients for signs and symptoms. Advise patients of the symptoms of heart failure and to immediately
report such symptoms. If heart failure develops, consider discontinuation of TRADJENTA or TRIJARDY XR.
Ketoacidosis: JARDIANCE, TRIJARDY XR
Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified
in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2)
inhibitors, including empagliflozin. Fatal cases of ketoacidosis have been reported in patients taking
empagliflozin. Patients who present with signs and symptoms of metabolic acidosis should be assessed for
ketoacidosis, even if blood glucose levels are less than 250 mg/dL. If suspected, discontinue, evaluate,
and treat promptly. Before initiating, consider risk factors for ketoacidosis. Patients may require
monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. For patients
who undergo scheduled surgery, consider temporarily discontinuing for at least 3 days prior to surgery.
Volume Depletion: JARDIANCE, TRIJARDY XR
Empagliflozin can cause intravascular volume depletion which may manifest as symptomatic hypotension or acute
transient changes in creatinine. Acute kidney injury requiring hospitalization and dialysis has been reported
in patients with type 2 diabetes receiving SGLT2 inhibitors, including empagliflozin. Before initiating, assess
volume status and renal function in patients with impaired renal function (eGFR<60 mL/min/1.73 m2), elderly
patients or patients on loop diuretics. After initiating, monitor for signs and symptoms of hypotension,
and renal function.
Urosepsis and Pyelonephritis: JARDIANCE, TRIJARDY XR
Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have
been identified in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2
inhibitors increases the risk for urinary tract infections. Evaluate for signs and symptoms of urinary
tract infections and treat promptly.
Hypoglycemia: JARDIANCE, TRADJENTA, TRIJARDY XR
The use in combination with insulin or insulin secretagogues can increase the risk of
hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required.
Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): JARDIANCE, TRIJARDY XR
Serious, life-threatening cases requiring urgent surgical intervention have occurred in both females and
males. Serious outcomes have included hospitalization, multiple surgeries and death. Assess patients
presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with
fever or malaise. If suspected, institute prompt treatment and discontinue JARDIANCE or TRIJARDY XR.
Genital Mycotic Infections: JARDIANCE, TRIJARDY XR
Empagliflozin increases the risk for genital mycotic infections, especially in patients with prior
infections. Monitor and treat as appropriate.
JARDIANCE: Serious hypersensitivity reactions have occurred with empagliflozin (angioedema).
If hypersensitivity reactions occur, discontinue JARDIANCE, treat promptly,
and monitor until signs and symptoms resolve.
TRADJENTA, TRIJARDY XR: Serious hypersensitivity reactions have occurred with linagliptin
(anaphylaxis, angioedema and exfoliative skin conditions) and empagliflozin (angioedema). If hypersensitivity
reactions occur, discontinue TRADJENTA or TRIJARDY XR, treat promptly,
and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema to another
DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema
with TRADJENTA or TRIJARDY XR.
Vitamin B12 Deficiency: TRIJARDY XR
Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually and
vitamin B12 at 2- to 3-year intervals.
Severe and Disabling Arthralgia: TRADJENTA, TRIJARDY XR
Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.
Consider linagliptin as a possible cause for severe joint pain and discontinue, if appropriate.
Bullous Pemphigoid: TRADJENTA, TRIJARDY XR
There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report
development of blisters or erosions. If bullous pemphigoid is suspected, discontinue.
MOST COMMON ADVERSE REACTIONS (≥5%)
JARDIANCE: urinary tract infections and female genital mycotic infections.
TRADJENTA: nasopharyngitis, hypoglycemia (when used in combination with sulfonylurea).
TRIJARDY XR: upper respiratory tract infections, urinary tract infection,
nasopharyngitis, diarrhea, constipation, headache, gastroenteritis.
JARDIANCE, TRIJARDY XR:
Coadministration of empagliflozin with diuretics may enhance the potential for volume depletion. Monitor for signs and symptoms.
Carbonic Anhydrase Inhibitors: The concomitant use of carbonic anhydrase inhibitors
(e.g., topiramate) and metformin may increase the risk of lactic acidosis. Consider more frequent monitoring.
Drugs that reduce metformin clearance such as ranolazine, vandetanib, dolutegravir,
or cimetidine may increase the accumulation of metformin and increase the risk of lactic acidosis.
Consider the benefits and risks of concomitant use.
Alcohol: Alcohol is known to potentiate the effect of metformin on lactate metabolism.
Warn patients against excessive alcohol intake while taking TRIJARDY XR.
TRADJENTA and TRIJARDY XR:
Inducers of P-glycoprotein or CYP3A4 Enzymes: The efficacy of linagliptin may be
reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Alternative
treatments should be used.
USE IN SPECIAL POPULATIONS
Pregnancy: JARDIANCE and TRIJARDY XR are not recommended during the second and third
trimesters. With TRIJARDY XR, discuss the potential for unintended pregnancy with
premenopausal women as therapy with metformin may result in ovulation in some anovulatory women.
Lactation: JARDIANCE or TRIJARDY XR are not recommended while breastfeeding.
Geriatric Use: With JARDIANCE or TRIJARDY XR, empagliflozin is expected
to have diminished efficacy in elderly patients with renal impairment. For TRIJARDY XR,
assess renal function more frequently in elderly patients, and dose selection should be cautious,
starting at the lowest dose. The incidence of volume depletion-related adverse reactions and urinary
tract infections increased in patients ≥75 years treated with empagliflozin.
Please see TRIJARDY XR
Prescribing Information, including Boxed Warning and
Please see JARDIANCE
Prescribing Information, including
Please see TRADJENTA
Prescribing Information, including
*3-in-1 pill is a fixed-dose combination treatment
†TRIJARDY XR Savings Card Terms & Conditions apply. Medicare/Medicaid/cash-paying patients
excluded from Savings Card enrollment.